Drug Trial Radar · NCT05817812
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Jul 31, 2023
Primary completion
Jun 2, 2026
Study completion Jun 2, 2026
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis. After a run-in period of 30-45 days, patients will receive efanesoctocog alfa prophylaxis, 50 IU/kg once-weekly for 24 months (additional preventive dose not permitted). An activity tracker and an electronic patient diary will be used to collect data on physical activity, bleeds, factor dosing, pain, and injuries from screening throughout the study. The primary objective is to describe changes in physical activities over 24 months on efanesoctocog alfa prophylaxis, with a primary endpoint of change from baseline in International Physical Activity Questionnaire (IPAQ) at month 24. Secondary objectives include relationship between physical activity and other variables (bleeds, joint status, pain, injuries, and quality of life); changes in joint status as assessed by HEAD-US, HJHS and MRI; occurrence of bleeds, injuries, pain. Safety and tolerability of efanesoctocog alfa will also be evaluated.
Conditions
- Hemophilia A, Severe
Interventions
Efanesoctocog alfaDrug
Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in International Physical Activity Questionnaire (IPAQ) scoringTime frame: Baseline and month 24
Locations
30 sites in 14 countries. Site status is shown where the registry gives one.
Investigational Site
Vienna, Austria
Investigational Site
Zagreb, Croatia
Investigational Site
Brno, Czechia
Investigational Site
Prague, Czechia
Investigational Site
Bordeaux, France
Investigational Site
Le Kremlin-Bicêtre, France
Investigational Site
Marseille, France
Investigational Site
Strasbourg, France
Investigational Site
Berlin, Germany
Investigational Site
Frankfurt, Germany
Investigational Site
Giessen, Germany
Investigational Site
Hamburg, Germany
Investigational Site
Athens, Greece
Investigational Site
Dublin, Ireland
Investigational Site
Catanzaro, Italy
Investigational Site
Florence, Italy
Investigational Site
Naples, Italy
Investigational Site
Parma, Italy
Investigational Site
Rome, Italy
Investigational Site
Utrecht, Netherlands
Investigational Site
Oslo, Norway
Investigational Site
Ljubljana, Slovenia
Investigational Site
Barcelona, Spain
Investigational Site
Madrid, Spain
Investigational Site
Oviedo, Spain
Investigational Site
Lund, Sweden
Investigational Site
Solna, Sweden
Investigational Site
Canterbury, United Kingdom
Investigational Site
Newcastle upon Tyne, United Kingdom
Investigational Site
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.